Oveporexton (TAK-861)(Takeda Pharmaceutical Co., Ltd.) · Aug 10, 2026 NDAPriority ReviewBreakthrough
Narcolepsy type 1 — caused by loss of the brain's orexin neurons, which normally produce the neuropeptide that stabilizes wakefulness.
Oveporexton is the first orexin receptor 2-selective agonist to reach the FDA. Where current narcolepsy treatments are wake-promoters that work around the deficiency — modafinil and pitolisant for sleepiness, sodium oxybate for cataplexy and night-sleep consolidation — oveporexton replaces the signal that's missing. Patients with NT1 have lost roughly 90% of their hypocretin/orexin neurons by the time they're diagnosed, leaving no endogenous wake-stabilizing signal. Takeda's Phase 3 FirstLight (adults) and RadiantLight (adolescents) both met all primary and secondary endpoints. Breakthrough and Priority Review designations. If approved, this is the first narcolepsy drug that targets the cause of the disease rather than its symptoms.
mRNA-1010(Moderna, Inc.) · Aug 5, 2026
Seasonal influenza — kills 30,000-60,000 Americans annually, and current egg-based vaccines have inconsistent efficacy because the production lag locks in strain choices made months before flu season starts.
mRNA-1010 would be the first mRNA-based seasonal flu vaccine approved anywhere. Moderna's bet is that the platform's faster manufacturing turnaround — weeks instead of months — lets the strains chosen by WHO each February be the strains in the vaccine by September. Egg-based production requires the strain commitment months earlier, which is one reason flu vaccines have averaged 40-60% effective across recent seasons. The Phase 3 program compared mRNA-1010 against standard inactivated quadrivalent vaccine in adults. If approved, this is Moderna's first major commercial expansion of the mRNA platform beyond COVID — and the proof case for whether mRNA can compete in a settled market with existing effective competitors.
Iberdomide + daratumumab/dexamethasone(Bristol-Myers Squibb Company) · Aug 17, 2026 NDAPriority ReviewBreakthrough
Relapsed or refractory multiple myeloma — patients who have failed prior lines including lenalidomide, the IMiD that revolutionized myeloma treatment.
Iberdomide is a CELMoD — a cereblon E3 ligase modulator engineered to recruit cereblon (the same E3 ligase thalidomide and lenalidomide accidentally bind) and degrade the transcription factors Ikaros and Aiolos with far greater potency than first-generation IMiDs. EXCALIBER-RRMM tested iberdomide combined with daratumumab and dexamethasone against lenalidomide-containing regimens in patients refractory to prior IMiD therapy. The CELMoD platform is BMS's bet on the next generation of cereblon-binding drugs — including mezigdomide (approved for myeloma 2024) and golcadomide in lymphoma. Breakthrough and Priority Review designations.
See also: Thalidomide Accidentally Invented Targeted Protein Degradation
Garetosmab(Regeneron Pharmaceuticals, Inc.) · Aug 19, 2026 BLAPriority ReviewBreakthrough
Fibrodysplasia ossificans progressiva — an ultra-rare genetic disease where soft tissue (muscle, ligaments, tendons) progressively turns into bone, eventually immobilizing patients.
Garetosmab is an anti-activin A monoclonal antibody that would be the first FDA-approved therapy for FOP. The disease is caused by a gain-of-function mutation in ACVR1, a bone-morphogenetic-protein receptor. Activin A — normally an inhibitor of ACVR1 — paradoxically activates the mutant receptor and drives the abnormal bone formation. Garetosmab blocks activin A from binding, removing the trigger. Phase 3 OPTIMA reported a greater than 99% reduction in new heterotopic ossification lesion volume vs placebo. The disease affects roughly 800 known patients globally. Three designations (Priority Review, Orphan, Breakthrough) reflect the unmet need. If approved, FOP joins the short list of monogenic ultra-rare diseases with a targeted therapy directed at the molecular driver.
